Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodine I-131 tositumomab + CHOP
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (chop), Intravenous (iodine I-131 Tositumomab)
01
Overview
This regimen is a **combination therapy** used in the treatment of advanced follicular and other non-Hodgkin lymphomas. It consists of six cycles of standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) followed by radioimmunotherapy with iodine I-131-labeled tositumomab (Bexxar), a murine anti-CD20 monoclonal antibody conjugated to radioactive iodine. - **CHOP** is cytotoxic and targets rapidly dividing cancer cells via four drugs: cyclophosphamide (alkylates DNA), doxorubicin (intercalates DNA and inhibits topoisomerase II), vincristine (inhibits microtubule formation), and prednisone (glucocorticoid cytotoxic to lymphocytes)[2][4]. - **Iodine I-131 tositumomab** binds to the CD20 antigen on B-cells, delivering targeted radiation, resulting in cell death via both the antibody’s immune effects and the cytotoxicity of the radioactive isotope[1][3][7]. - The regimen showed improved rates of complete response in clinical trials compared to CHOP alone, with manageable toxicity and a high overall response rate[1][3][7]. - Developed for the treatment of advanced follicular lymphoma and investigated in diffuse large B-cell lymphoma[1][3][7].
- Brand names
- Bexxar
- Other names
- iodine I-131 tositumomabtositumomabCHOPcyclophosphamide + doxorubicin + vincristine + prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on iodine I-131 tositumomab + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodine I-131 tositumomab + CHOP.